company background image
ACCD

AccoladeNasdaqGS:ACCD Stock Report

Market Cap

US$2.8b

7D

-5.2%

1Y

25.5%

Updated

25 Sep, 2021

Data

Company Financials +
ACCD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ACCD Overview

Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States.

Accolade Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Accolade
Historical stock prices
Current Share PriceUS$43.06
52 Week HighUS$32.37
52 Week LowUS$65.25
Beta0
1 Month Change-1.65%
3 Month Change-18.62%
1 Year Change25.47%
3 Year Changen/a
5 Year Changen/a
Change since IPO44.98%

Recent News & Updates

Shareholder Returns

ACCDUS HealthcareUS Market
7D-5.2%-2.2%0.1%
1Y25.5%33.6%35.3%

Return vs Industry: ACCD underperformed the US Healthcare industry which returned 37.5% over the past year.

Return vs Market: ACCD underperformed the US Market which returned 37.5% over the past year.

Price Volatility

Is ACCD's price volatile compared to industry and market?
ACCD volatility
ACCD Beta0
Industry Beta0.87
Market Beta1

Stable Share Price: ACCD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ACCD's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20071,900Raj Singhhttps://www.accolade.com

Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services.

Accolade Fundamentals Summary

How do Accolade's earnings and revenue compare to its market cap?
ACCD fundamental statistics
Market CapUS$2.85b
Earnings (TTM)-US$85.40m
Revenue (TTM)US$193.99m

14.7x

P/S Ratio

-33.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACCD income statement (TTM)
RevenueUS$193.99m
Cost of RevenueUS$107.37m
Gross ProfitUS$86.62m
ExpensesUS$172.02m
Earnings-US$85.40m

Last Reported Earnings

May 31, 2021

Next Earnings Date

Oct 07, 2021

Earnings per share (EPS)-1.29
Gross Margin44.65%
Net Profit Margin-44.02%
Debt/Equity Ratio63.9%

How did ACCD perform over the long term?

See historical performance and comparison

Valuation

Is Accolade undervalued compared to its fair value and its price relative to the market?

6.51x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ACCD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ACCD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ACCD is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: ACCD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ACCD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ACCD is overvalued based on its PB Ratio (6.5x) compared to the US Healthcare industry average (3.2x).


Future Growth

How is Accolade forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

16.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACCD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACCD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACCD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACCD's revenue (29.9% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: ACCD's revenue (29.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ACCD is forecast to be unprofitable in 3 years.


Past Performance

How has Accolade performed over the past 5 years?

-1.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ACCD is currently unprofitable.

Growing Profit Margin: ACCD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ACCD is unprofitable, and losses have increased over the past 5 years at a rate of 1.9% per year.

Accelerating Growth: Unable to compare ACCD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACCD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (32.2%).


Return on Equity

High ROE: ACCD has a negative Return on Equity (-19.54%), as it is currently unprofitable.


Financial Health

How is Accolade's financial position?


Financial Position Analysis

Short Term Liabilities: ACCD's short term assets ($453.5M) exceed its short term liabilities ($167.5M).

Long Term Liabilities: ACCD's short term assets ($453.5M) exceed its long term liabilities ($286.9M).


Debt to Equity History and Analysis

Debt Level: ACCD's debt to equity ratio (63.9%) is considered high.

Reducing Debt: Insufficient data to determine if ACCD's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACCD has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ACCD has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 5.3% each year


Dividend

What is Accolade current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACCD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACCD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACCD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACCD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACCD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Raj Singh (53 yo)

5.92yrs

Tenure

US$2,592,000

Compensation

Mr. Rajeev Singh, also known as Raj, serves as Director at Amperity, Inc. He has been the Chief Executive Officer and Executive Director of Accolade, Inc. since October 2015 and also serves as its Chairman...


CEO Compensation Analysis

Compensation vs Market: Raj's total compensation ($USD2.59M) is below average for companies of similar size in the US market ($USD5.25M).

Compensation vs Earnings: Raj's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ACCD's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: ACCD's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.2%.


Top Shareholders

Company Information

Accolade, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Accolade, Inc.
  • Ticker: ACCD
  • Exchange: NasdaqGS
  • Founded: 2007
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$2.845b
  • Shares outstanding: 66.07m
  • Website: https://www.accolade.com

Number of Employees


Location

  • Accolade, Inc.
  • 660 West Germantown Pike
  • Suite 500
  • Plymouth Meeting
  • Pennsylvania
  • 19462
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 02:22
End of Day Share Price2021/09/24 00:00
Earnings2021/05/31
Annual Earnings2021/02/28


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.